US 2021/0061870 A1 · METHOD AND SYSTEM FOR EXTRACTING NEOANTIGENS FOR IMMUNOTHERAPY

Abstract

A method and system for extracting neoantigens for immunotherapy includes the following steps: step S1: acquiring conventional proteomes of tumor tissue and normal tissue samples; step S2: acquiring nucleotide polymer sequence libraries of the tumor tissue and normal tissue samples and a specific proteome of the tumor tissue sample; step S3: acquiring a plurality of candidate tumor-specific neoantigens based on the conventional and specific proteomes of the tumor tissue sample and molecular human leukocyte antigen (HLA) typing; and step S4: calculating the presence of the plurality of candidate tumor-specific neoantigens in the conventional proteomes and the nucleotide polymer sequence libraries of the tumor tissue and normal tissue samples, and acquiring tumor-specific neoantigens with a multiple of gene expression changes as a filter rule. More tumor-specific neoantigens are discovered using the new method because they are not limited to coding regions and are partly derived from genome noncoding regions (NCRs).

Claims8

Dependent claims

A method for extracting neoantigens for immunotherapy, comprising:

step S1:
acquiring a conventional proteome of a tumor tissue sample and a conventional proteome of a normal tissue sample;
step S2:
acquiring nucleotide polymer sequence libraries of the tumor tissue sample and the normal tissue sample, and a specific proteome of the tumor tissue sample;
step S3:
acquiring a plurality of candidate tumor-specific neoantigens based on the conventional proteome of the tumor tissue sample and the specific proteome of the tumor tissue sample, and acquiring molecular human leukocyte antigen (HLA) typing;
and
step S4:
separately calculating feature values of the plurality of candidate tumor-specific neoantigens based on the plurality of candidate tumor-specific neoantigens acquired, and acquiring tumor-specific neoantigens by filtering under a preset rule.

6 more elements

A system for extracting neoantigens for immunotherapy, comprising:

a conventional proteome acquiring unit, used for acquiring a conventional proteome of a tumor tissue sample and a conventional proteome of a normal tissue sample;
a specific proteome acquiring unit, used for acquiring nucleotide polymer sequence libraries of the tumor tissue sample and the normal tissue sample, and a specific proteome of the tumor tissue sample;
a candidate neoantigen determining unit, used for acquiring a plurality of candidate tumor-specific neoantigens based on the conventional proteome of the tumor tissue sample and the specific proteome of the tumor tissue sample, and for acquiring molecular human leukocyte antigen (HLA) typing;
and
a tumor-specific neoantigen determining unit, used for separately calculating feature values of the plurality of candidate tumor-specific neoantigens based on the plurality of candidate tumor-specific neoantigens acquired, and acquisition of tumor-specific neoantigens by filtering under a preset rule.

2 more elements

Dependencies are inferred from the claim text.

Method and system for extracting neoantigens for immunotherapy

Life of this patent

Method and system for extracting neoantigens for immunotherapy

Life of this patent

Abstract

Claims8